<p>Immunome（纳斯达克：IMNM - 获取免费报告）在周一发布给客户和投资者的研究报告中被高盛集团的股票研究人员升级为 “强力买入” 评级，Zacks.com 报道。</p>
<ul>
<li>3 只小盘股具有巨大的增长潜力</li>
</ul>
<p>其他几家研究公司也最近对 IMNM 发表了看法。Guggenheim 在 8 月 25 日的研究报告中重申了 “买入” 评级，并对 Immunome 的股票设定了 25.00 美元的目标价。摩根大通将 Immunome 的股票目标价从 23.00 美元下调至 22.00 美元，并在 8 月 7 日的研究报告中为该公司设定了 “增持” 评级。Wedbush 在 9 月 18 日的研究报告中重申了 “跑赢大盘” 评级，并对 Immunome 的股票设定了 21.00 美元的目标价。Evercore ISI 在 8 月 22 日的研究报告中开始覆盖 Immunome 的股票，给予 “跑赢大盘” 评级，并设定了 18.00 美元的目标价。最后，Craig Hallum 在 9 月 5 日的研究报告中开始覆盖 Immunome 的股票，给予 “买入” 评级，并设定了 26.00 美元的目标价。一位投资分析师对该股票给予了强力买入评级，九位分析师对该公司的股票给予了买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “买入”，共识目标价为 23.20 美元。</p>
<p><strong>获取我们关于 Immunome 的最新股票报告</strong></p>
<h2>Immunome 股价上涨 4.0%</h2>
<p>IMNM 周一开盘价为 9.77 美元。该公司的市值为 8.5038 亿美元，市盈率为-3.17，贝塔值为 1.92。Immunome 的 1 年最低价为 5.15 美元，1 年最高价为 15.40 美元。该公司的 50 日移动平均价格为 10.03 美元，200 日移动平均价格为 8.84 美元。</p>
<p>Immunome（纳斯达克：IMNM - 获取免费报告）最近在 8 月 6 日发布了季度财报。该公司报告季度每股收益为（0.50 美元），超出市场共识预期的（0.52 美元）0.02 美元。该公司在本季度的收入为 402 万美元，而分析师预期为 103 万美元。Immunome 的净利润率为-1687.08%，股本回报率为-76.10%。平均而言，研究分析师预测 Immunome 在当前年度的每股收益为-2.21 美元。</p>
<h2>Immunome 的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近对该公司的持仓进行了调整。T. Rowe Price Investment Management Inc.在第一季度将其在 Immunome 的持股增加了 37.4%。T. Rowe Price Investment Management Inc.目前拥有 7554594 股该公司的股票，价值 50843000 美元，此前在上个季度购买了 2054640 股。Redmile Group LLC 在第一季度将其在 Immunome 的持股增加了 11.0%。Redmile Group LLC 目前拥有 5361187 股该公司的股票，价值 36081000 美元，此前在上个季度购买了 533161 股。Vanguard Group Inc.在第一季度将其在 Immunome 的持股增加了 43.4%。Vanguard Group Inc.目前拥有 4307191 股该公司的股票，价值 28987000 美元，此前在上个季度购买了 1303753 股。EcoR1 Capital LLC 在第一季度将其在 Immunome 的持股增加了 5.2%。EcoR1 Capital LLC 目前拥有 4079415 股该公司的股票，价值 27454000 美元，此前在上个季度购买了 200000 股。最后，Primecap Management Co. CA 在第一季度将其在 Immunome 的持股增加了 1115.7%。Primecap Management Co. CA 目前拥有 3413700 股该公司的股票，价值 22974000 美元，此前在上个季度购买了 3132900 股。44.58% 的股票目前由机构投资者和对冲基金持有。</p>
<h2>关于 Immunome</h2>
<p>（获取免费报告）</p>
<p>Immunome, Inc.是一家生物技术公司，开发靶向癌症疗法。该公司的临床资产包括 AL102，一种正在评估的伽马分泌酶抑制剂，目前正在进行针对纤维瘤的三期试验；前临床资产包括 IM-1021，一种受体酪氨酸激酶样孤儿受体 1 和抗体药物偶联物，以及 IM-3050，一种针对成纤维细胞活化蛋白的放射性配体疗法；以及 IM-4320，一种抗 IL-38 免疫疗法候选药物。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Immunome 更好</li>
<li>什么是盈利惊喜？</li>
<li>疲软的美元如何推动这些全球股票的飙升</li>
<li>投资者需要了解即将上市的 IPO</li>
<li>3 只在经济低迷时表现良好的股票</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>3 只被低估的自动化股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Immunome 吗？</h2>
<p>在你考虑 Immunome 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Immunome 并不在名单上。</p>
<p>虽然 Immunome 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IMNM

<p>高盛集团在最近的一份研究报告中将 Immunome（NASDAQ:IMNM）的评级上调至 “强烈买入”。包括古根海姆和摩根大通在内的其他公司也对该股票给予了积极的评级和价格目标。Immunome 的股票开盘价为 9.77 美元，市值为 8.5038 亿美元。该公司报告的季度收益超出预期，收入大幅超过预期。机构投资者已增加对 Immunome 的持股，该公司专注于开发靶向癌症疗法</p>

<p>Immunome (NASDAQ:IMNM - Get Free Report) was upgraded by equities researchers at The Goldman Sachs Group to a &#34;strong-buy&#34; rating in a research report issued to clients and investors on Monday,Zacks.com reports.</p>
<div class="lb-trans"><p>Immunome（纳斯达克：IMNM - 获取免费报告）在周一发布给客户和投资者的研究报告中被高盛集团的股票研究人员升级为 “强力买入” 评级，Zacks.com 报道。</p>
</div><ul>
<li>3 Small-Cap Stocks With Big Growth Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盘股具有巨大的增长潜力</li>
</ul>
</div><p>Several other research firms have also recently weighed in on IMNM. Guggenheim restated a &#34;buy&#34; rating and issued a $25.00 price objective on shares of Immunome in a research report on Monday, August 25th. JPMorgan Chase &amp; Co. lowered their price objective on shares of Immunome from $23.00 to $22.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday, August 7th. Wedbush restated an &#34;outperform&#34; rating and issued a $21.00 price objective on shares of Immunome in a research report on Thursday, September 18th. Evercore ISI began coverage on shares of Immunome in a research report on Friday, August 22nd. They issued an &#34;outperform&#34; rating and a $18.00 price objective for the company. Finally, Craig Hallum began coverage on shares of Immunome in a research note on Friday, September 5th. They issued a &#34;buy&#34; rating and a $26.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $23.20.</p>
<div class="lb-trans"><p>其他几家研究公司也最近对 IMNM 发表了看法。Guggenheim 在 8 月 25 日的研究报告中重申了 “买入” 评级，并对 Immunome 的股票设定了 25.00 美元的目标价。摩根大通将 Immunome 的股票目标价从 23.00 美元下调至 22.00 美元，并在 8 月 7 日的研究报告中为该公司设定了 “增持” 评级。Wedbush 在 9 月 18 日的研究报告中重申了 “跑赢大盘” 评级，并对 Immunome 的股票设定了 21.00 美元的目标价。Evercore ISI 在 8 月 22 日的研究报告中开始覆盖 Immunome 的股票，给予 “跑赢大盘” 评级，并设定了 18.00 美元的目标价。最后，Craig Hallum 在 9 月 5 日的研究报告中开始覆盖 Immunome 的股票，给予 “买入” 评级，并设定了 26.00 美元的目标价。一位投资分析师对该股票给予了强力买入评级，九位分析师对该公司的股票给予了买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “买入”，共识目标价为 23.20 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Immunome</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Immunome 的最新股票报告</strong></p>
</div><h2>Immunome Trading Up 4.0%</h2>
<div class="lb-trans"><h2>Immunome 股价上涨 4.0%</h2>
</div><p>IMNM opened at $9.77 on Monday. The stock has a market capitalization of $850.38 million, a PE ratio of -3.17 and a beta of 1.92. Immunome has a 1-year low of $5.15 and a 1-year high of $15.40. The firm has a 50-day moving average price of $10.03 and a two-hundred day moving average price of $8.84.</p>
<div class="lb-trans"><p>IMNM 周一开盘价为 9.77 美元。该公司的市值为 8.5038 亿美元，市盈率为-3.17，贝塔值为 1.92。Immunome 的 1 年最低价为 5.15 美元，1 年最高价为 15.40 美元。该公司的 50 日移动平均价格为 10.03 美元，200 日移动平均价格为 8.84 美元。</p>
</div><p>Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.02. The firm had revenue of $4.02 million during the quarter, compared to analysts' expectations of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. On average, research analysts predict that Immunome will post -2.21 EPS for the current year.</p>
<div class="lb-trans"><p>Immunome（纳斯达克：IMNM - 获取免费报告）最近在 8 月 6 日发布了季度财报。该公司报告季度每股收益为（0.50 美元），超出市场共识预期的（0.52 美元）0.02 美元。该公司在本季度的收入为 402 万美元，而分析师预期为 103 万美元。Immunome 的净利润率为-1687.08%，股本回报率为-76.10%。平均而言，研究分析师预测 Immunome 在当前年度的每股收益为-2.21 美元。</p>
</div><h2>Institutional Trading of Immunome</h2>
<div class="lb-trans"><h2>Immunome 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. raised its holdings in shares of Immunome by 37.4% in the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company's stock valued at $50,843,000 after purchasing an additional 2,054,640 shares during the last quarter. Redmile Group LLC raised its holdings in shares of Immunome by 11.0% in the first quarter. Redmile Group LLC now owns 5,361,187 shares of the company's stock valued at $36,081,000 after purchasing an additional 533,161 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Immunome by 43.4% in the first quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company's stock valued at $28,987,000 after purchasing an additional 1,303,753 shares during the last quarter. EcoR1 Capital LLC increased its holdings in Immunome by 5.2% during the first quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company's stock worth $27,454,000 after buying an additional 200,000 shares during the last quarter. Finally, Primecap Management Co. CA increased its holdings in Immunome by 1,115.7% during the first quarter. Primecap Management Co. CA now owns 3,413,700 shares of the company's stock worth $22,974,000 after buying an additional 3,132,900 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对该公司的持仓进行了调整。T. Rowe Price Investment Management Inc.在第一季度将其在 Immunome 的持股增加了 37.4%。T. Rowe Price Investment Management Inc.目前拥有 7554594 股该公司的股票，价值 50843000 美元，此前在上个季度购买了 2054640 股。Redmile Group LLC 在第一季度将其在 Immunome 的持股增加了 11.0%。Redmile Group LLC 目前拥有 5361187 股该公司的股票，价值 36081000 美元，此前在上个季度购买了 533161 股。Vanguard Group Inc.在第一季度将其在 Immunome 的持股增加了 43.4%。Vanguard Group Inc.目前拥有 4307191 股该公司的股票，价值 28987000 美元，此前在上个季度购买了 1303753 股。EcoR1 Capital LLC 在第一季度将其在 Immunome 的持股增加了 5.2%。EcoR1 Capital LLC 目前拥有 4079415 股该公司的股票，价值 27454000 美元，此前在上个季度购买了 200000 股。最后，Primecap Management Co. CA 在第一季度将其在 Immunome 的持股增加了 1115.7%。Primecap Management Co. CA 目前拥有 3413700 股该公司的股票，价值 22974000 美元，此前在上个季度购买了 3132900 股。44.58% 的股票目前由机构投资者和对冲基金持有。</p>
</div><h2>About Immunome</h2>
<div class="lb-trans"><h2>关于 Immunome</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.</p>
<div class="lb-trans"><p>Immunome, Inc.是一家生物技术公司，开发靶向癌症疗法。该公司的临床资产包括 AL102，一种正在评估的伽马分泌酶抑制剂，目前正在进行针对纤维瘤的三期试验；前临床资产包括 IM-1021，一种受体酪氨酸激酶样孤儿受体 1 和抗体药物偶联物，以及 IM-3050，一种针对成纤维细胞活化蛋白的放射性配体疗法；以及 IM-4320，一种抗 IL-38 免疫疗法候选药物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Immunome</li>
<li>What is an Earnings Surprise?</li>
<li>How The Weak Dollar Is Fueling These Global Stock Surges</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>3 Recession-Ready Stocks That Thrive When the Economy Sputters</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>3 Automation-Focused Stocks Flying Under the Radar</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Immunome 更好</li>
<li>什么是盈利惊喜？</li>
<li>疲软的美元如何推动这些全球股票的飙升</li>
<li>投资者需要了解即将上市的 IPO</li>
<li>3 只在经济低迷时表现良好的股票</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>3 只被低估的自动化股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=IMNM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunome Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Immunome 吗？</h2>
</div><p>Before you consider Immunome, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Immunome 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Immunome 并不在名单上。</p>
</div><p>While Immunome currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Immunome 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Immunome（纳斯达克股票代码：IMNM）被高盛集团升级为 “强力买入” 评级